AOD-9604 timeline: what to expect week by week

Last updated 2026-07-24

What does the actual AOD-9604 research say happened, and when?

The honest starting point is this: AOD-9604 went through human obesity trials in the mid-2000s, and the results did not show a weight-loss effect that separated convincingly from placebo. A 2004 review in Current Opinion in Investigational Drugs describes AOD-9604 as a fragment of human growth hormone engineered to isolate the fat-metabolizing (lipolytic) region of the hGH molecule while dropping the growth-promoting region ^[1]. That is the whole rationale for the drug: HGH burns fat partly through a specific domain, so why not extract just that domain and skip the side effects that come with full-length HGH? It is a smart idea on paper. The problem is that when it got tested in people at obesity-relevant doses, it did not produce a clean, reproducible fat-loss signal that beat placebo by a wide margin. A separate 2006 survey of obesity drugs in clinical development from the same journal lists AOD-9604 among the compounds being tracked through that era's anti-obesity pipeline, alongside many others that also failed to reach approval ^[2]. So when a seller or forum post gives you a day-by-day 'expect this by week 3, this by week 6' timeline, understand that timeline is not coming from the human trial data. It is either extrapolated from anecdote, borrowed from HGH or other peptide timelines, or simply invented to sound credible. Nobody has published a solid dose-response curve in humans showing when fat loss shows up on AOD-9604, because the trials did not show a fat loss effect worth timing.

So is there any real timeline to expect, or not?

There is a timeline for the things that are actually measurable: your injection routine, your tolerance, and your body's local reaction to the injections. There is not a reliable timeline for fat loss, because the trial evidence for a fat loss effect over placebo is not there ^[1]. Week 1 to 2 is habit-building. If you are reconstituting and injecting a peptide, this stretch is about getting the reconstitution volume right, picking an injection site rotation, and watching for redness or swelling at the site. See our guide on how to reconstitute AOD-9604 if you are at this stage. Week 3 to 6 is where most anecdotal reports claim to notice something, waistline changes, appetite shifts, energy changes. None of this is backed by a controlled human trial showing AOD-9604 outperforming placebo at this timepoint. Treat any change you notice during this window with real skepticism, because normal diet and activity changes (the kind that happen when someone starts a new protocol and pays closer attention to their food) can easily produce the same result with no peptide involved at all. Week 8 to 12 is the natural decision point. If you have been logging body composition markers (weight, waist circumference, or better, actual body fat testing) and nothing has moved beyond what you'd expect from your diet and training changes, that is the point to stop and reassess, not to double the dose.

Why did the human obesity trials not show a clear fat-loss timeline?

The short answer: the fragment hypothesis did not translate cleanly from animal and cell models into a reliable human effect at the doses tested. The 2004 review in Current Opinion in Investigational Drugs is the primary human-relevant reference here, and it frames AOD-9604 specifically around its lipolytic fragment design without reporting the kind of clean placebo-beating efficacy data you'd want to see before recommending a dosing timeline ^[1]. This is a common story in the obesity drug pipeline. The 2006 review covering obesity drugs in clinical development lists a long roster of candidates from that era, most of which never made it to approval ^[2]. AOD-9604 is one name on that list, not a standout with a distinct approval pathway or a strong Phase 3 result behind it. If AOD-9604 had produced a strong, reproducible signal, it would likely show up in the approved drug record. It is not there. You can check any given peptide's approval status yourself through the FDA's Drugs@FDA database ^[3], which lists every drug the agency has formally approved, and AOD-9604 does not appear as an approved product. This is also why the compounding pathway matters so much to how this product actually reaches people today. Under federal law, a compounding pharmacy can only prepare a drug from a bulk substance if that substance is on FDA's approved bulks list for 503A pharmacies ^[4] or 503B outsourcing facilities ^[5], under the authority of 21 U.S.C. 353a ^[6]. FDA also maintains a running list of substances nominated for compounding consideration, which is a very different thing from an approved list ^[7]. None of that legal machinery changes the underlying efficacy question. It just tells you AOD-9604 is being handled as a compounded research or off-label substance, not an FDA-approved obesity drug with an approved dosing schedule and timeline.

What happens in the first week of taking AOD-9604?

In week one, expect the physical adjustment period, not fat loss. If you're using a subcutaneous injection protocol, the first few days typically involve mild injection-site redness, minor bruising, or a small welt that resolves within a day or two. This is standard for any subcutaneous peptide injection, not specific to AOD-9604's mechanism. This is also the period where dosing habits get formed or broken. Getting the reconstitution ratio consistent, injecting at a similar time each day, and rotating sites are the practical things that actually matter in week one. None of that is glamorous, but it's what determines whether the rest of a cycle goes smoothly. Our AOD-9604 dosage guide and dosage calculator cover the practical reconstitution math if you're at this stage. What you should not expect in week one: measurable fat loss, meaningful appetite suppression tied specifically to the peptide, or any effect distinguishable from what a week of clean eating would produce on its own.

When (if ever) does AOD-9604 start working for fat loss?

Based on the published human trial record, there isn't a documented point at which AOD-9604 reliably 'starts working' for fat loss, because the controlled trials didn't show it working over placebo in the first place ^[1]. Anecdotal reports online cluster around the 4 to 8 week mark, but anecdote is not the same as evidence, and none of those reports come from controlled comparisons. Compare that to what we know works. Diet-induced caloric deficits reliably produce fat loss on a predictable timeline that has been studied for decades. FDA-approved obesity treatments, which you can verify through the Drugs@FDA database ^[3], went through Phase 3 trials specifically designed to establish a dose and duration where the drug beat placebo by a statistically and clinically meaningful margin. AOD-9604 did not clear that bar in its own obesity development program ^{[1] [2]}. If you're deciding whether to try it anyway, the honest framing is: you are testing an unproven compound on yourself, on a timeline nobody has established, using outcome measures (your own scale weight, your own tape measure) that are easily influenced by lifestyle changes happening at the same time.

How does the AOD-9604 timeline compare to other peptides or approaches?

A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews looked at therapeutic peptides used in orthopaedic applications and flagged ongoing challenges around evidence quality and regulatory status across this broader peptide category, not AOD-9604 specifically for fat loss ^[8]. A related 2026 review in Sports Medicine examined safety and efficacy across approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, again a broader category assessment rather than an AOD-9604 fat-loss verdict ^[9]. Neither of these papers rescues AOD-9604's obesity trial record. They do tell you the peptide space generally has evidence gaps that regulators and researchers are actively trying to close. If your actual goal is fat loss with evidence behind the timeline, an FDA-approved option with Phase 3 data is the stronger bet. If you're specifically curious about AOD-9604 for reasons beyond fat loss, read the AOD-9604 peptide overview for the full mechanism and trial history before deciding anything about dosing schedules.

Does AOD-9604 show up on a drug test, and does that affect timing?

This matters if you're an athlete thinking about timing a cycle around competition. A 2013 study in Drug Testing and Analysis specifically tested whether AOD-9604 interferes with the WADA hGH isoform immunoassay, the test used to detect growth hormone doping, and found that it does not influence that particular assay ^[10]. That does not mean AOD-9604 is untestable in general, only that it does not throw off that one specific test. Separately, anti-doping labs have developed other detection methods aimed specifically at peptides like AOD-9604. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis reviews analytical approaches for detecting emerging therapeutics and non-approved drugs in doping controls, explicitly covering compounds in this category ^[11]. A companion 2014 review in Expert Review of Proteomics covers detection strategies for peptidic drugs, drug candidates, and analogs in sports doping more broadly ^[12]. And a 2016 method published in the Journal of Separation Science describes a direct urine injection technique using liquid chromatography and ion mobility mass spectrometry built to screen for peptides under 2 kDa, a size range that includes AOD-9604 ^[13]. The practical takeaway: if you compete under a testing body, assume detection methods exist and are improving, and there is no safe timing window based on old assumptions that small peptides fly under the radar.

What should you track week by week if you decide to try it anyway?

If you're going ahead despite the thin trial evidence, track things that are actually measurable and comparable, not vibes. Baseline (day 0): weight, waist circumference at the navel, and ideally a body fat percentage from a consistent method (DEXA, calipers from the same person, or a bioelectrical scale used the same time of day). Take a photo under consistent lighting. Weekly: same three measurements, same time of day, same conditions. Note any injection-site reactions, sleep changes, appetite changes, and anything else you're doing differently (new diet, new training block, new supplement). This last part is the one people skip and it's the one that matters most, because it's the confound that explains most 'it worked' reports. Week 8 to 12 checkpoint: compare your numbers against what a caloric deficit alone would predict for someone at your starting weight and activity level. If your results are in line with what diet and training changes would produce on their own, you don't have evidence the peptide did anything. That's not a knock on your effort, it's just what the human trial record predicted would happen ^[1].

What are the realistic safety and side-effect timing concerns?

Injection-site reactions (redness, mild swelling, occasional bruising) tend to show up in the first days after starting and usually settle as technique improves and sites get rotated. Beyond local reactions, the published safety data specific to AOD-9604 in humans is thin, which is a direct consequence of the same trial record that failed to establish efficacy. The 2026 Sports Medicine review of peptide therapies for musculoskeletal and athletic use covers safety considerations across a range of approved and unapproved peptides, and is a useful general reference for the kind of monitoring anyone using an unapproved peptide should be doing (injection site, systemic symptoms, and awareness that long-term human safety data is often incomplete for compounds outside the approved drug list) ^[9]. For everything you should watch for and how long to watch for it, read the full AOD-9604 side effects guide before you start, not after something goes wrong. Because AOD-9604 is handled through the compounding pathway rather than as an FDA-approved product ^{[4] [5] [6]}, there is no standardized, agency-reviewed patient labeling telling you what adverse event rates to expect at what point in a cycle. That absence itself is worth weighing before you commit to a 12-week protocol.

If the trial data is weak, why do people still buy AOD-9604?

Mostly because the fragment story is genuinely compelling on paper, and it's easy to find enthusiastic anecdotal reports online that don't mention the trial record at all. The mechanism (isolating hGH's lipolytic domain while dropping the growth-promoting domain) is real chemistry, described accurately in the 2004 review ^[1]. It's just that a plausible mechanism is not the same as a demonstrated effect in controlled human trials, and AOD-9604's obesity program is the clearest example of that gap. If you're going to buy it anyway, the sourcing decision matters more than most people realize, because quality and purity vary a lot between suppliers in this unregulated space. AOD-9604 Co reviews providers along a compounding-pharmacy-fulfilled pathway, meaning the product moves through a licensed pharmacy rather than an unregulated research-chemical seller, which at least gets you closer to a consistent, tested product even though it doesn't change the underlying efficacy question. See AOD-9604 for sale for how that review process works and what to look for in a provider. The honest bottom line for a timeline article: there is a real timeline for injection habits, tolerance, and your own decision point at 8 to 12 weeks. There is no honest human-trial timeline for fat loss, because the trials didn't show the effect in the first place ^{[1] [2]}.

Frequently asked questions

How long does it take for AOD-9604 to start working?

There's no reliable answer from human trial data, because the controlled obesity trials on AOD-9604 didn't show a fat-loss effect that beat placebo ^[1]. Anecdotal reports mention 4 to 8 weeks, but that's not backed by a controlled comparison, so treat any personal timeline claim with skepticism.

What should I expect in the first week of AOD-9604?

Expect adjustment to injection routine, not fat loss. Mild injection-site redness or minor bruising is common in week one and typically resolves as technique and site rotation improve. There's no evidence base for expecting measurable fat loss changes this early.

Did AOD-9604 pass human obesity trials?

No. AOD-9604 went through human obesity trials, but the weight-loss results did not separate convincingly from placebo ^[1]. It never reached FDA approval as an obesity treatment, and it does not appear in the FDA's Drugs@FDA database of approved drugs ^[3].

How long should I try AOD-9604 before deciding it isn't working?

A reasonable checkpoint is 8 to 12 weeks, tracking weight, waist circumference, and ideally body fat percentage against a consistent baseline. If your results track what diet and training alone would predict, there's no evidence the peptide contributed anything beyond that.

Does AOD-9604 show up on a doping test?

A 2013 study found AOD-9604 does not influence the WADA hGH isoform immunoassay specifically ^[10]. However, separate detection methods targeting small peptides under 2 kDa have since been developed and published ^{[11] [12] [13]}, so assume detectability exists through other assays.

Is AOD-9604 FDA approved?

No. AOD-9604 is not an FDA-approved drug. It's typically supplied through the compounding pathway, which requires the active substance to appear on FDA's approved bulk drug substances lists for 503A pharmacies ^[4] or 503B facilities ^[5] under 21 U.S.C. 353a ^[6].

What's the difference between AOD-9604's timeline and an approved obesity drug's timeline?

FDA-approved obesity drugs went through Phase 3 trials establishing a specific dose and duration where they beat placebo by a meaningful margin, verifiable through Drugs@FDA ^[3]. AOD-9604 never cleared that bar in its own obesity development program ^{[1] [2]}, so no equivalent regulator-reviewed timeline exists.

Can injection-site reactions tell me anything about whether AOD-9604 is working?

No. Injection-site redness, swelling, or bruising reflects the mechanics of subcutaneous injection, not the peptide's fat-metabolism activity. These reactions are common with any subcutaneous peptide and aren't evidence the compound is producing a systemic effect.

Should I combine AOD-9604 with diet and exercise, or test it alone?

If you want any honest read on whether the peptide itself is doing anything, you'd need to isolate it from diet and training changes, which is exactly what controlled trials try to do and what home use can't replicate. Realistically, most people change several things at once, which makes self-reported results unreliable.

How does AOD-9604's evidence compare to other peptides used for injuries or performance?

A 2026 orthopaedic review and a 2026 Sports Medicine review both examined peptide therapies for musculoskeletal and athletic use more broadly, describing a mixed evidence landscape across approved and unapproved peptides ^{[8] [9]}. Neither paper reverses AOD-9604's specific obesity trial outcome, which remains the central data point for fat-loss claims.

What does 'gateways to clinical trials' mean in AOD-9604's research history?

It refers to a recurring pharmacology journal series from the early-to-mid 2000s that tracked compounds entering clinical development, including AOD-9604 during that period ^{[14] [15] [16]}. Being tracked through a development pipeline is not the same as demonstrating efficacy in a completed trial.

Is there an official reconstitution or dosing timeline for AOD-9604?

No FDA-approved labeling exists for AOD-9604, so there's no regulator-reviewed dosing schedule. Practical reconstitution steps are covered in our how to reconstitute and dosage guides, but these reflect common compounding practice, not clinical trial protocols.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604's fragment design targets the lipolytic region of hGH; human obesity trial results did not separate convincingly from placebo
2. PubMed, Current Opinion in Investigational Drugs (2006): AOD-9604 is listed among obesity drug candidates in clinical development during that era, most of which did not reach approval
3. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product in the Drugs@FDA database
4. eCFR, 21 CFR 216.23 (503A Bulks List): 503A compounding pharmacies may only use bulk substances on FDA's approved bulks list
5. eCFR, 21 CFR 216.24 (503B Bulks List): 503B outsourcing facilities operate under a separate approved bulk substances list
6. Cornell Law, 21 U.S.C. 353a: Federal statute governing pharmacy compounding authority under section 503A
7. FDA, bulk drug substances nominated for compounding (current list): FDA maintains a nominated substances list separate from the approved bulks list
8. PubMed, JAAOS Global Research & Reviews (2026): Review of therapeutic peptides in orthopaedic applications flags evidence and regulatory challenges across the peptide category
9. PubMed, Sports Medicine (2026): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
10. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay used to detect growth hormone doping
11. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Review of analytical approaches for detecting emerging therapeutics and non-approved drugs in doping controls
12. PubMed, Expert Review of Proteomics (2014): Review of detection strategies for peptidic drugs, drug candidates, and analogs in sports doping
13. PubMed, Journal of Separation Science (2016): Method for direct urine injection LC-ion mobility mass spectrometry screening of peptides under 2 kDa
14. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Gateways to clinical trials series tracked AOD-9604 among compounds entering development in this period
15. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Gateways to clinical trials series entry from 2003 tracking compounds in development
16. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): Gateways to clinical trials series entry from 2005 tracking compounds in development